IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2019
NCT03762564
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

IKF Klinische Krebsforschung GmbH | IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Universitätsklinikum Frankfurt Goethe-Universität

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Biliary Tract Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cholangiocarcinoma (Phase 2)

Esophageal Neoplasms (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Fibrosis (Phase 2)

Liver Cirrhosis (Phase 2)

Lung Neoplasms (Phase 2)

Rectal Neoplasms (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial APIs: 26